Current Issue February 2012, Vol. 8, No. 2

Feature Article

Gadolinium metallofullerenol nanoparticles inhibit cancer metastasis through matrix metalloproteinase inhibition: imprisoning instead of poisoning cancer cellsFree

The purpose of this work is to study the antimetastasis activity of gadolinium metallofullerenol nanoparticles (f-NPs) in malignant and invasive human breast cancer models. We demonstrated that f-NPs inhibited the production of matrix metalloproteinase (MMP) enzymes and further interfered with the invasiveness of cancer cells in tissue culture condition.

Issue Highlights

  • Initial Studies of Mechanical Compression on Neurogenesis with Neonatal Neural Stem Cells
    27 January 2012

    Leyla Esfandiari, Michelle Paff, William C. Tang

  • pH-Dependent Nanostructure Based on Isoquinoline-Cyclodextrin Conjugate for Thrombosis Therapy
    16 January 2012

    Li Li, Ming Zhao, Wenhao Li, Yuji Wang, Chunna Liu, Zhuge Zhang, Songchun Su, Shiqi Peng

  • Improving interstitial transport of macromolecules through reduction in cell volume fraction in tumor tissues
    16 January 2012

    Sarah McGuire, Fan Yuan

  • Electrostatic Assembly of a DNA Superparamagnetic Nanotool for Simultaneous Intracellular Delivery and In-Situ Monitoring
    16 January 2012

    Frédéric Geinguenaud, Inès Souissi, Remi Fagard, Laurence Motte, Yoann Lalatonne

  • Harnessing Nanoparticles to Improve Toxicity after Head and Neck Radiation
    16 January 2012

    Rafael A. Madero-Visbal, Beatrice E. Alvarado, Jimmie F. Colon, Cheryl H. Baker, Melissa S. Wason, Beth Isley, Sudipta Seal, Chris M. Lee, Soumen Das, Rafael Mañon

  • View More Articles in Press...

On the Cover


Cover Image


About Nanomedicine: NBM

Nanomedicine: Nanotechnology, Biology and Medicine is an international, peer-reviewed journal. Each issue of Nanomedicine: NBM presents theoretical and experimental research results related to nanoscience and nanotechnology in life sciences, including Basic, Translational, and Clinical research, and commercialization of results. Article formats include Communications, Original Articles, Reviews, Perspectives, Technical and Commercialization Notes, Letters to the Editor, and Case Reports. In addition, regular features on our website will address commercialization, funding opportunities, and societal, Public Health, and ethical issues of nanomedicine. We invite authors to submit original manuscripts in these categories.

More


Publishing Information

Nanomedicine: Nanotechnology, Biology and Medicine is published by Elsevier.

Access this journal onSciVerse ScienceDirect
Print or Share This Page

Journal Ranking

Impact Factor

Nanomedicine: NBM 2010 impact factor: 4.882
Nanomedicine: NBM now ranks 13th of 63 journals in the Nanoscience and Nanotechnology subject category on the 2010 Journal Citation Reports®, published by Thomson Reuters.

Journal Access

Full-text articles are available from 2005 to the present. Access to abstracts, editorials, perspectives, and feature articles is complimentary.

Activate Online Access

Nanomedicine: NBM News

Updated Scope and Author instructions: Both About the journal and Author Information pages have recently been updated. Please read our more focused scope statement to decide whether to submit your manuscript. Author Information now describes the editorial decisions we use. Journal policy puts limitations on timeline of resubmissions.

Nanomedicine: NBM thanks its 2010 reviewers. The editorial team gratefully acknowledges its 2010 reviewers, and thanks them for their invaluable expertise and input. We especially thank those reviewers who completed 4 or more reviews in 2010.